Cagrilintide
A long-acting amylin analogue studied for once-weekly appetite and weight-regulation research.
What Cagrilintide is
Cagrilintide is a synthetic, fatty-acid–acylated analogue of amylin designed for extended circulating exposure. Amylin is a pancreatic peptide co-secreted with insulin; researchers study cagrilintide because it engages amylin-family receptors involved in satiety signaling, gastric emptying, and energy-intake control. Unlike native amylin, the engineered structure supports once-weekly subcutaneous investigation in clinical research settings.
Interest accelerated after dose-finding and combination studies paired cagrilintide with GLP-1 receptor agonists such as semaglutide (often discussed as CagriSema). Published phase 1–3 programs have evaluated monotherapy and fixed-dose combinations for body-weight and metabolic endpoints under controlled protocols. All material discussed here is framed for research use only.
For laboratory and literature work, cagrilintide is typically handled as a lyophilized peptide or prefilled clinical-trial presentation. Research teams track titration schedules carefully because gastrointestinal tolerability in trials improved when doses were escalated rather than started at the top of the tested range.
Cagrilintide has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
Cagrilintide activates amylin receptors (calcitonin receptor paired with receptor activity–modifying proteins). Downstream signaling in brainstem and hypothalamic circuits is associated with reduced food intake and slower gastric emptying in experimental models. Lipidation prolongs albumin binding and extends plasma half-life into a multi-day window, which is why weekly subcutaneous regimens appear in published protocols rather than multiple daily native-amylin dosing.
Who works with it, and what they are measuring
Metabolic disease groups, obesity-pharmacology labs, and clinical trial units studying next-generation weight-management peptides track cagrilintide closely. Formulation and PK teams also use it as a case study in acylated long-acting peptide design. Interest is research-focused; it is not presented here as a consumer therapy.
What the research examines
These describe where the compound shows up in published work. None of them should be read as an established outcome.
How it appears in the literature
Taken from the methods sections of the cited work. Not a recommendation.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Phase 2 monotherapy dose-finding (once-weekly SC) | 300 mcg – 4.5 mg | once weekly | subcutaneous |
| Phase 1b combination with semaglutide | 160 mcg – 4.5 mg | once weekly | subcutaneous |
Handling & storage
Lyophilized peptide is typically stored refrigerated or frozen per supplier COA, protected from light and moisture. After reconstitution with bacteriostatic water, research labs generally refrigerate and use within the stability window stated on the lot documentation.
Notes on combined research
The best-documented research pairing is with semaglutide (CagriSema), combining amylin-pathway and GLP-1-pathway pharmacology. Literature discussions sometimes place it alongside other incretin or nutrient-stimulated hormone analogues when mapping multi-agonist weight-regulation strategies. Stacking references describe controlled trial designs, not informal self-directed protocols.
Cagrilintide questions
Published clinical research most often cites once-weekly subcutaneous doses from about 0.3 mg up to 4.5 mg, frequently after gradual escalation. Combination programs commonly highlight a 2.4 mg weekly anchor dose paired with semaglutide. These figures are documented trial exposures, not personal-use instructions.
Research reconstitution volume depends on vial strength and target concentration. For a 5 mg vial, 2–3 mL bacteriostatic water is a common laboratory starting point so that weekly milligram doses can be measured with an insulin syringe. Always follow the specific COA and protocol math for the lot in use.
Cagrilintide is not typically described as a daily peptide in modern trials. Its long half-life supports once-weekly subcutaneous schedules in the published clinical literature.
Trial publications and protocols outline escalation tables (for example stepping through 0.3 → 0.6 → 1.2 → 2.4 → 4.5 mg weekly). Any chart derived from those papers should be treated as a literature reference tool for research planning only.
Phase 1b pharmacokinetic work reported plasma half-life values of roughly 159–195 hours, consistent with weekly dosing designs.
Yes in the narrow research sense: controlled studies have co-administered cagrilintide with semaglutide. That is a formal dual-agonist research program, not a recommendation to combine research chemicals outside approved studies.
No. It is a long-acting amylin analogue engineered for extended exposure. Pramlintide is a different amylin mimetic with a much shorter clinical dosing cadence.
Independent research-supply listings often show multi-milligram lyophilized vials (commonly discussed around 5–10 mg). Clinical trial product presentations differ and are protocol-specific.
Read the research yourself
Verified against PubMed, one by one. A reference you cannot open is not evidence.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.PubMed
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.PubMed